RecruitingPhase 4NCT06864403

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Studying Pouchitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of North Carolina, Chapel Hill
Principal Investigator
Edward Barnes, MD, MPH
University of North Carolina
Intervention
Mirikizumab - Intravenous (IV)(drug)
Enrollment
25 target
Eligibility
18-80 years · All sexes
Timeline
20252027

Study locations (5)

Collaborators

Eli Lilly and Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06864403 on ClinicalTrials.gov

Other trials for Pouchitis

Additional recruiting or active studies for the same condition.

See all trials for Pouchitis

← Back to all trials